Omalizumab True statement is-
**Core Concept**
Omalizumab is a recombinant humanized monoclonal antibody that targets the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the release of mediators involved in allergic reactions.
**Why the Correct Answer is Right**
Omalizumab works by binding to IgE molecules, preventing them from binding to the FcεRI receptor on mast cells and basophils. This leads to a decrease in the release of histamine and other mediators, resulting in reduced symptoms of allergic diseases such as asthma and rhinitis. Omalizumab is particularly useful in patients with severe allergic asthma who are not adequately controlled with inhaled corticosteroids.
**Why Each Wrong Option is Incorrect**
**Option A:** Omalizumab is administered orally. This is incorrect because Omalizumab is administered subcutaneously.
**Option B:** Omalizumab increases IgE levels. This is incorrect because Omalizumab binds to IgE molecules, reducing their levels and activity.
**Option C:** Omalizumab is used to treat autoimmune disorders. This is incorrect because Omalizumab is specifically used to treat allergic diseases, not autoimmune disorders.
**Clinical Pearl / High-Yield Fact**
Omalizumab is a high-efficacy treatment for severe allergic asthma, particularly in patients with a high IgE level and a history of anaphylaxis. It is essential to monitor IgE levels and adjust the dose accordingly to minimize the risk of anaphylaxis.
**Correct Answer: C. Omalizumab is a recombinant humanized monoclonal antibody that targets the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the release of mediators involved in allergic reactions.**